Lu-177 decays by beta emission and gamma emission with a half-life of 6.65 days. It is typically produced in nuclear reactors by neutron irradiation of lutetium-176. The resulting Lu-177 is then chemically separated and incorporated into radiopharmaceuticals. Supply chain considerations involve the availability of nuclear reactors, lutetium-176 targets, and radiochemistry facilities. Logistical challenges include the transport and handling of radioactive materials. Accessibility for developing countries is limited by the specialised facilities and regulatory requirements.
Overview
Maturity
Lu-177 production and application are well-established, with increasing use in targeted radionuclide therapy.
Safety considerations
Lu-177 is a radioactive isotope that emits beta and gamma radiation, requiring careful handling and shielding to minimise radiation exposure.
Security considerations
While Lu-177 is not a proliferation concern, proper control and monitoring are necessary to prevent unauthorised access or misuse.
Safeguarding considerations
Traditional IAEA safeguards are not directly applicable due to the absence of fissile materials. However, monitoring and verification of the production and use of Lu-177 may be considered to ensure transparency and prevent misuse.